Nurix reports 92.9% response rate for BTK degrader bexobrutideg in CLL patients

Nurix Therapeutics announced updated Phase 1a/b clinical trial results showing a 92.9% objective response rate in second-line CLL patients treated with bexobrutideg, with durable responses in heavily pretreated patients and promising activity in earlier treatment lines. The positive data supports advancement toward Phase 3 trials and potential best-in-class positioning for this investigational BTK degrader.